Aethlon Medical Reports Q1 FY2027 Results, $4.9M Cash, and 12-Month Runway
AEMD is trading near its 52-week low of $2.625 (13% above the low) on light trading volume (0.1× avg).
Summary
Aethlon Medical reported Q1 FY2027 results with a narrower net loss, $4.9M in cash, and a post-quarter $4.0M raise, extending runway to at least 12 months. The Hemopurifier Phase 1 study advanced to its final cohort.
Key Events · Earnings and Guidance · AEMD
-
Q1 FY2027 Net Loss Narrows
Net loss was $1.55 million, down from $1.76 million in the prior-year quarter, driven by an 11.9% reduction in operating expenses to $1.6 million.
-
Cash Runway Extended to 12 Months
Cash and equivalents were $4.9 million as of June 30, 2026, and a post-quarter public offering raised approximately $4.0 million in gross proceeds. Management states cash is sufficient for at least the next 12 months.
-
Hemopurifier Phase 1 Advances
First participant was dosed in the third and final cohort of the Phase 1 oncology study in Australia. Early biomarker signals from initial cohorts support continued evaluation.
-
Long COVID Publication Accepted
A manuscript on extracellular vesicle characteristics in Long COVID patients was accepted for publication in the International Journal of Molecular Sciences.
Analysis · AEMD · Industrial Applications And Services
Aethlon Medical reported Q1 FY2027 results with a net loss of $1.55 million, down from $1.76 million a year earlier, and operating expenses down 11.9% to $1.6 million. Cash stood at $4.9 million as of June 30, 2026, and the company raised approximately $4.0 million in gross proceeds after quarter-end. Management states cash is sufficient for at least the next 12 months, addressing the going-concern risk flagged in the June 10-K. The Hemopurifier program advanced with the first participant dosed in the third and final cohort of the Phase 1 oncology study in Australia, and a Long COVID manuscript was accepted for publication. This is the first disclosure of quarterly results and updated runway guidance, making it a material update for investors.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29% of the 1483 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AEMD was trading at $2.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $2.63 to $137.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.